Publications by authors named "A Kverneland"

Protein identification and quantification is an important tool for biomarker discovery. With the increased sensitivity and speed of modern mass spectrometers, sample preparation remains a bottleneck for studying large cohorts. To address this issue, we prepared and evaluated a simple and efficient workflow on the Opentrons OT-2 robot that combines sample digestion, cleanup, and loading on Evotips in a fully automated manner, allowing the processing of up to 192 samples in 6 h.

View Article and Find Full Text PDF

Background And Purpose: Immune therapy with checkpoint inhibitors (CPIs) is a highly successful therapy in many cancers including metastatic melanoma. Still, many patients do not respond well to therapy and there are no blood-borne biomarkers available to assess the clinical outcome.

Materials And Methods: To investigate cellular changes after CPI therapy, we carried out flow cytometry-based immune monitoring in a cohort of 90 metastatic melanoma patients before and after CPI therapy using the FlowSOM algorithm.

View Article and Find Full Text PDF

Background: Adoptive cell therapy (ACT) has shown promising results for the treatment of cancer and viral infections. Successful ACT relies on ex vivo expansion of large numbers of desired T-cells with strong cytotoxic capacity and in vivo persistence, which constitutes the greatest challenge to current ACT strategies. Here, in this study, we present a novel technology for ex vivo expansion of antigen-specific T-cells; artificial antigen-presenting scaffolds (Ag-scaffolds) consisting of a dextran-polysaccharide backbone, decorated with combinations of peptide-Major Histocompatibility Complex (pMHC), cytokines and co-stimulatory molecules, enabling coordinated stimulation of antigen-specific T-cells.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the efficacy and safety of a vaccine combining Bcl-XL-derived peptides and the adjuvant CAF09b in patients with hormone-sensitive prostate cancer, aiming to enhance immune responses against cancer cells.
  • Twenty patients were divided into two groups: one received intramuscular (IM) vaccinations followed by intraperitoneal (IP), while the other group received IP first and then IM, monitoring safety and immune response.
  • Results showed no serious adverse events and indicated that patients receiving the IP first demonstrated stronger and earlier immune responses, with significant activation of CD4 and CD8 T cell markers after vaccination.
View Article and Find Full Text PDF

Cancer survival and progression depend on the ability of tumor cells to avoid immune recognition. Advances in the understanding of cancer immunity and tumor immune escape mechanisms enabled the development of immunotherapeutic approaches. In patients with otherwise incurable metastatic cancers, immunotherapy resulted in unprecedented response rates with the potential for durable complete responses.

View Article and Find Full Text PDF